Different Oral Doses of Clindamycin in Preventing Post-operative Sequelae of Lower Third Molar Surgery
NCT05268835 is a phase 4 interventional trial sponsored by Oral and Maxillofacial Surgery Clinic, Poland. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies Dalacin C in Impacted Molar and Impacted Third Molar Tooth. The registry lists an enrollment of 300 participants at 1 site in 1 country. The registry lists a start date of 1 Feb 2020 and a primary completion date of 31 Aug 2022.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05268835 |
| Status | Unknown |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Oral and Maxillofacial Surgery Clinic, Poland |
| Enrollment | 300 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Impacted Molar and Impacted Third Molar Tooth |
| Drugs | Dalacin C |
| Start | 1 Feb 2020 |
| Primary completion | 31 Aug 2022 |
| Study completion | 31 Oct 2022 |
| Last update posted | 7 Mar 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Anna Janas-Naze, DMD,PhD,Prof
OMFS Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Omfs Clinic
Zgierz
Anna Janas-Naze, DMD,PhD,ProfRecruiting
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05268835
Each answer restates registry values shown on this page.
What is NCT05268835?
NCT05268835 is a phase 4 interventional trial sponsored by Oral and Maxillofacial Surgery Clinic, Poland. It studies Dalacin C in Impacted Molar and Impacted Third Molar Tooth.
Who leads NCT05268835?
The registry names Anna Janas-Naze, DMD,PhD,Prof (principal investigator, OMFS Clinic) as the overall official.
Where does NCT05268835 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: Poland.
Which drugs does NCT05268835 study?
The registered drug and biological interventions are Dalacin C.
When is NCT05268835 expected to complete?
The registry lists a primary completion date of 31 Aug 2022 and a study completion date of 31 Oct 2022. The sponsor last updated the record on 7 Mar 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.